Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Cash from Financing Activities (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Cash from Financing Activities for 13 consecutive years, with $132964.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 102.08% to $132964.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $519595.0, a 2.19% decrease, with the full-year FY2025 number at $452430.0, down 28.32% from a year prior.
  • Cash from Financing Activities was $132964.0 for Q4 2025 at Regen BioPharma, down from $227799.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.4 million in Q3 2021 to a low of -$94535.0 in Q4 2021.
  • A 5-year average of $181961.5 and a median of $132964.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 99.96% in 2022, then surged 28707.62% in 2023.
  • Regen BioPharma's Cash from Financing Activities stood at -$94535.0 in 2021, then soared by 100.53% to $499.0 in 2022, then soared by 33125.85% to $165797.0 in 2023, then crashed by 60.31% to $65799.0 in 2024, then skyrocketed by 102.08% to $132964.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Cash from Financing Activities are $132964.0 (Q4 2025), $227799.0 (Q3 2025), and $55976.0 (Q2 2025).